Real-world adherence, healthcare resource utilization, and costs following a transition to aripiprazole once every 2 months among patients diagnosed with bipolar I disorder in the United States


Creative Commons License

Nag S. S., Urganus A., Bell Lynum K. S., Atkins N., Baser O., Rodchenko K., ...Daha Fazla

Frontiers in Psychiatry, cilt.17, 2026 (SCI-Expanded, SSCI, Scopus)

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17
  • Basım Tarihi: 2026
  • Doi Numarası: 10.3389/fpsyt.2026.1904737
  • Dergi Adı: Frontiers in Psychiatry
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Social Sciences Citation Index (SSCI), Scopus, EMBASE, Psycinfo, Directory of Open Access Journals
  • Anahtar Kelimeler: adherence - compliance - persistence, aripiprazole monohydrate, bipolar I disorder, healthcare resource utilization (HCRU), long-acting injectable (LAI), real-world evidence (RWE), retrospective cohort study
  • Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
  • Boğaziçi Üniversitesi Adresli: Evet

Özet

Introduction – Transitioning from oral to long-acting injectable (LAI) antipsychotics may improve adherence and reduce healthcare resource utilization (HCRU) in patients living with bipolar I disorder (BP-I), with potentially greater improvements with LAIs with dosing intervals longer than 1 month. Aripiprazole monohydrate is available as LAI formulations administered once-monthly [aripiprazole once-monthly (AOM)] or once every 2 months (aripiprazole 2-month ready-to-use [Ari 2MRTU]). This pre-post analysis described adherence, HCRU, and costs over 6 months in adults diagnosed with BP-I who transitioned from oral antipsychotics or AOM to Ari 2MRTU. Methods – This retrospective, noninterventional study used Kythera Labs United States closed claims to identify adults diagnosed with BP-I, commercially or Medicaid-insured, and who transitioned from oral antipsychotics or AOM to Ari 2MRTU from April 2023–September 2024 (index date = Ari 2MRTU transition). Continuous enrollment for 12 months pre- and 6 months post-index was required. Study outcomes were compared 6 months prior to and following the index date. Results – Among those who transitioned from oral antipsychotics to Ari 2MRTU (n = 371), mean proportion of days covered (PDC) increased from 0.60 to 0.76 (26.2% relative increase), mean medication possession ratio (MPR) increased from 0.67 to 0.85 (26.8% relative increase), and proportion of patients with MPR ≥ 0.8 increased from 41.2% to 72.0% (74.5% relative increase) (all P < 0.0001). Notable reductions in all-cause inpatient visits and length of stay (LOS) were observed, along with reductions in BP-I–related LOS and emergency department (ED) visits. All-cause inpatient, ED, and total medical (inpatient, outpatient, ED) costs declined. Among those who transitioned from AOM to Ari 2MRTU (n = 1, 096), mean PDC increased from 0.56 to 0.81 (45.3% relative increase), mean MPR increased from 0.62 to 0.89 (43.7% relative increase), and proportion of patients with MPR ≥ 0.8 increased from 51.2% to 79.0%) (54.4% relative increase) (all P < 0.0001). Inpatient visits (all-cause, BP-I–related), and all-cause LOS decreased, along with all-cause ED and total medical costs. Discussion – Transitioning to Ari 2MRTU was associated with improved treatment adherence and reduced selected HCRU measures and total medical costs, supporting its value as a treatment option for BP-I.